![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
ACT-334441 (cenerimod), is a highly selective S1P1 receptor modulator, being investigated as an oral once-daily tablet. Cenerimod potentially offers a novel approach for the treatment of SLE, a disease with a significant impact on patients and limited treatment options.
Lead Product(s): Cenerimod
Therapeutic Area: Immunology Product Name: ACT-334441
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
Cenerimod 4 mg showed clinically meaningful improvement in mSLEDAI-2K primary efficacy endpoint and other measures of efficacy, consistent with the effect seen on biological activity. Cenerimod, novel S1P1 receptor modulator an oral treatment of systemic lupus erythematosus.
Lead Product(s): Cenerimod
Therapeutic Area: Immunology Product Name: ACT-334441
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021